Agios is a biopharmaceutical company founded in 2008 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapies for rare diseases, with a particular focus on cellular metabolism. Since its founding, Agios has evolved from a discovery-stage organization into a commercial-stage enterprise, securing FDA approval for its first rare disease therapy to treat hemolytic anemia in adults with pyruvate kinase deficiency.
The company's pipeline includes mitapivat, a medicine in clinical development for thalassemia and sickle cell disease. Agios operates across the full spectrum of drug development, from research laboratories through clinical development and commercial operations, alongside patient engagement and regulatory functions.
The organization emphasizes inclusion, collaboration, and patient-centricity across its operations. Agios cultivates relationships with patient communities, healthcare professionals, and scientific partners, positioning patient needs at the center of its work. The company describes a culture that values diverse backgrounds and encourages employees to bring their whole selves to work, whether physically or virtually.
